MS lifeline as a drug that can slow down the listed… – AlKhaleej Today

Patients with multiple sclerosis have been granted a lifeline by the federal government listing a drug that can slow the progression of the disease. The move means that all patients who could benefit from Mayzent will only have to pay $ 41 per script, instead of the estimated annual cost of $ 25,000.
Multiple sclerosis, known as MS, is the most common acquired neurological disease in younger adults, with more than 25,600 Australians living with the disease.
The average age at diagnosis is only…

Click here to view the original article.